DNAtrix is a company developing modified viruses for the treatment of the most aggressive forms of cancer. Since viruses are already efficient at killing cells, scientists have harnessed this ability by modifying a common cold virus so that it targets and selectively kills cancer cells. DNAtrix is a privately held company located in Houston, Texas and San Diego, California.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/14/14 | $20,000,000 | Series B |
Mercury Fund Morningside Group Targeted Technology Fund | undisclosed |
